| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Jean-Guy Baril | Q121183517 |
| P2093 | author name string | Marianne Harris | |
| Jonathan B Angel | |||
| Anita Rachlis | |||
| Benoit Trottier | |||
| P2860 | cites work | Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. | Q51910874 |
| Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. | Q51910877 | ||
| HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response. | Q53005466 | ||
| British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008 | Q57180178 | ||
| Roles of Conformational and Positional Adaptability in Structure-Based Design of TMC125-R165335 (Etravirine) and Related Non-nucleoside Reverse Transcriptase Inhibitors That Are Highly Potent and Effective against Wild-Type and Drug-Resistant HIV-1 V | Q57480046 | ||
| Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America | Q28183380 | ||
| Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol | Q28469069 | ||
| Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r | Q31051809 | ||
| Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials | Q31108441 | ||
| Clinical uses of non-nucleoside reverse transcriptase inhibitors | Q33966241 | ||
| Transection of the oesophagus for bleeding oesophageal varices | Q34211834 | ||
| Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study | Q34546335 | ||
| TMC-125 Tibotec. | Q35713959 | ||
| Update of the drug resistance mutations in HIV-1: 2007. | Q36919747 | ||
| Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel | Q37234205 | ||
| HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. | Q39593854 | ||
| TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. | Q40425001 | ||
| TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments | Q42033549 | ||
| Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure | Q44118757 | ||
| Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia | Q44457921 | ||
| A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects | Q44644287 | ||
| An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance | Q44699308 | ||
| Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine | Q45193916 | ||
| Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial | Q45405108 | ||
| Evaluating the role of etravirine in the second-line antiretroviral therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting | Q46316162 | ||
| Successful rescue therapy with Raltegravir (MK-0518) and Etravirine (TMC125) in an hiv-infected patient failing all four classes of antiretroviral drugs | Q46676615 | ||
| Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks | Q46798933 | ||
| Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers | Q46808283 | ||
| Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors | Q46968863 | ||
| Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance | Q47776364 | ||
| Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis | Q48472661 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e24-34 | |
| P577 | publication date | 2009-01-01 | |
| P1433 | published in | Canadian Journal of Infectious Diseases & Medical Microbiology | Q5030243 |
| P1476 | title | Canadian consensus guidelines for the optimal use of etravirine in the treatment of HIV-infected adults | |
| P478 | volume | 20 |
Search more.